# A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

> **NCT03210961** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 109 (actual)

## Conditions studied

- Plaque Psoriasis

## Interventions

- **DRUG:** PF-06826647 tablet
- **DRUG:** PF-06826647 oral suspension
- **OTHER:** Placebo oral solution/suspension
- **OTHER:** Placebo tablet

## Key facts

- **NCT ID:** NCT03210961
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-14
- **Primary completion:** 2019-01-25
- **Final completion:** 2019-01-25
- **Target enrollment:** 109 (ACTUAL)
- **Last updated:** 2020-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03210961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03210961, "A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03210961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*